Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

Abstract

Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting. Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal.